- Related Products
MedEx answers any queries you might have regarding Ibrutinib-140 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Ibrutinib 140 mg is intended for the treatment of mantle cell lymphoma, chronic lymphocytic leukaemia (CLL) and Waldenstrom’s macroglobulinaemia (WM).
During the treatment with Ibrutinib 140 mg you should take it at about the same time every day with a glass of water. Try to stay hydrated during the day. Remember that you should swallow the pills (instead of breaking or chewing them). According to some drug providers, this drug must be taken on an empty stomach (1 hour before or 2 hours after the meal). However, certain pharmacokinetic researches indicate that Ibrutinib can be taken irrespective of the mealtime.
Ibrutinib is a breakthrough in the treatment of chronic lymphocytic leukaemia. It is considered a safe drug. However, any treatment involves risks. By informing yourself and listening to your organism you will probably profit from this medications and be able to detect potential complications and risks in your therapy.
Mechanism of action.
Ibrutinib 140 mg can suppress the activity of tyrosine kinase. This enzyme represents an important link, necessary to activate several metabolic processes in the cancer cell. By preventing the activity of this enzyme, Imbruvica finally destroys the cancer cells.
Way of use.
Ibrutinib 140 mg comes in the form of capsules, intended for the oral intake. The capsules shouldn’t be broken. You must swallow them with any liquid (except for grapefruit juice). In case of mantle cell lymphoma, the standard dosage is 560 mg once a day. For the treatment of chronic bovine leukosis, the standard dose of Imbruvica is 420 mg once a day. The treatment should continue until the patient notices a clinical response from the treatment or until he/she develops severe adverse effects.
Effectiveness of use.
According to the clinical test data, the general frequency of response to the therapy with Imbruvica was 69%. Besides, more than 78% of patients demonstrated the increase of survival rate without the progress of disease (compared to the control group that didn’t receive this drug); moreover, the risk of fatal outcome reduced.